Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 100 K
USD 77 K
Funding amount
Introduction: Bladder cancer (BCa) is currently one of the most expensive cancers to treat, and with many promising but costly therapies emerging, BCa treatment costs are expected to increase even further. As a result, research that assesses how to effectively distribute our resources will be essential for insurers and governmental funding agencies as they make BCa funding-related decisions. This study will develop a Canadian Policy Model (CPM) in BCa, which will allow us to determine the cost-effectiveness of new BCa drugs and interventions. Methods: All possible health states that BCa patients experience will be identified and mapped to simulate patient transitions through their disease pathway (e.g., from diagnosis, through treatments, to recovery/recurrence/death). We will then obtain (i) the costs of each health state, (ii) health outcomes and (iii) quality of life for each health state in the form of "utilities." These data will serve as inputs for our CPM. For population-level, health state-specific costs, we will link cancer staging data to data on Ontario BCa patient procedures, physician billings and drug usage, which are available at the Institute for Clinical Evaluative Sciences. Health outcomes data (e.g., probabilities of complications, recurrence, progression, etc.) will be collected by systematically reviewing published literature. To obtain BCa utilities, we will prospectively give our newly created BCa-specific "utility"-generating questionnaire, the Bladder Utility Symptom Scale (BUSS), to BCa patients at three large BCa centres (University Health Network, McGill University Health Centre, Vancouver General Hospital). Impact: Once developed, the CPM will provide a means for comparing the effectiveness and cost implications of new and emerging BCa treatment strategies. Overall, the final CPM will contribute to more informed, evidence-based best practices in BCa treatment, resulting in better patient management and the reduction of healthcare costs.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting TAM (Tyro3-Axl-Mer) family of transmembrane receptor tyrosine kinases in bladder cancer.

Bladder Cancer Advocacy Network to Arpita Roy

USD 1,700
2018 - 2018
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023
Project list item
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)

National Cancer Institute to HEIDI ANNE HANSON

USD 298,810
2018 - 2023
Project list item
Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of Smokers

National Cancer Institute to NAGIREDDY PUTLURI, RANDA A EL-ZEIN

USD 1,202,103
2018 - 2023



    1117 Public Health and Health Services

  • RCDC

    Health Services

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Comparative Effectiveness Research

  • RCDC

    Urologic Diseases




    8.2 Health and welfare economics

  • Health Research Areas

    Health services & systems

  • Broad Research Areas

    Health Services Research